IMUC - ImmunoCellular Therapeutics, Ltd.
| Previous Close | 0.2702 |
| Open | 0.2750 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.2606 - 0.2750 |
| 52 Week Range | 0.1700 - 2.7900 |
| Volume | 269,971 |
| Avg. Volume | 1,375,696 |
| Market Cap | 11.103M |
| Beta | 0.27 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.2280 |
| Earnings Date | Aug 24, 2017 - Aug 25, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.00 |
- ACCESSWIRE•5 days ago
Blog Exposure - ImmunoCellular Therapeutics Reported Achievement of Next Key Milestone in Validating Stem-to-T-Cell Program
Stock Monitor: Alpine Immune Sciences Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 16, 2018 / Active-Investors.com has just released a free research report on ImmunoCellular Therapeutics, Ltd ...
- PR Newswire•9 days ago
ImmunoCellular Therapeutics Announces Achievement of Next Key Milestone in Stem-to-T-Cell Research Immuno-Oncology Program
LOS ANGELES, April 12, 2018 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the Company) (NYSE American: IMUC) announced today that it has been able to verify successful transfer of the selected T cell receptor genetic material into human hematopoietic stem cells. This milestone represents the next important step in validating the Stem-to-T-Cell approach, and is a key component of the proof-of-concept work for this technology.
- PR Newswire•26 days ago
ImmunoCellular Therapeutics Receives Audit Opinion with Going Concern Explanation
LOS ANGELES , March 26, 2018 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE American: IMUC) today announced that, as previously disclosed in its Annual Report on Form ...
- Thomson Reuters StreetEvents•last month
Edited Transcript of IMUC earnings conference call or presentation 13-Mar-18 9:00pm GMT
Q4 2017 ImmunoCellular Therapeutics Ltd Earnings Call
- PR Newswire•last month
ImmunoCellular Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results
-Continued Progress in Stem-to-T-Cell Program- -Strengthened Financial Condition- -Conference Call Today at 5:00 pm ET- LOS ANGELES , March 13, 2018 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") ...
- ACCESSWIRE•last month
ImmunoCellular Therapeutics, Ltd. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 13, 2018 / ImmunoCellular Therapeutics, Ltd. (NYSE American: IMUC ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 13, 2018, at ...
- ACCESSWIRE•last month
Today’s Research Reports on Trending Tickers: ImmunoCellular Therapeutics and Spectrum Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / March 7, 2018 / U.S. markets had a topsy-turvy day as concerns of a potential trade war, a result of tariffs proposed by President Donald Trump, continue to worry investors. ...
- PR Newswire•last month
ImmunoCellular Therapeutics to Report Fourth Quarter and Full Year 2017 Financial Results on March 13, 2018
LOS ANGELES , March 7, 2018 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE American: IMUC) today announced that it plans to report fourth quarter and full year 2017 ...
- GlobeNewswire•2 months ago
Consolidated Research: 2018 Summary Expectations for People's United Financial, American International Group, ImmunoCellular Therapeutics, W&T Offshore, ONEOK, and Avon Products — Fundamental Analysis, Key Performance Indications
NEW YORK, March 06, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- PR Newswire•2 months ago
ImmunoCellular Therapeutics Announces Review of Strategic Alternatives
LOS ANGELES, Feb. 22, 2018 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE American: IMUC), a biotechnology company developing immunotherapies for the treatment of cancer based on its Stem-to-T-Cell research program, announced today that it has retained Ladenburg Thalmann & Co. Inc. as its strategic financial advisor to assist in the review of the Company's business and assets and exploration of strategic opportunities for enhancing stockholder value, including the potential sale or merger of the Company. The Company cannot guarantee that this process will culminate in a transaction.
- ACCESSWIRE•2 months ago
Today’s Research Reports on Trending Tickers: Catabasis Pharmaceuticals and ImmunoCellular Therapeutics
NEW YORK, NY / ACCESSWIRE / February 14, 2018 / Strong performances from banking and technology stocks helped lift the markets further into the green on Tuesday. The Dow Jones Industrial Average gained ...
- ACCESSWIRE•2 months ago
2 Medical Stocks Trending on Today's News
CORAL GABLES, FL / ACCESSWIRE / February 13, 2018 / Medical, biotech, and pharmaceutical stocks have been trending higher since President Trump came into office. In his first year following the inauguration, ...
- PR Newswire•2 months ago
ImmunoCellular Therapeutics Announces Update on Financial Condition
Strengthened Financial Condition Supports Continued Advancement of Stem-to-T-Cell Program LOS ANGELES , Feb. 13, 2018 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE ...
- ACCESSWIRE•4 months ago
Today’s Research Reports on Trending Tickers: ImmunoCellular Therapeutics and Marinus Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / December 15, 2017 / Progress of the recent tax bill hit a snag on Thursday as two GOP Senators raised some concerns. All sectors closed down on Thursday dragging markets lower, ...
- PR Newswire•4 months ago
ImmunoCellular Therapeutics Achieves Key Milestone in Stem-to-T-Cell Research Immuno-Oncology Program
LOS ANGELES, Dec. 13, 2017 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the Company) (NYSE American: IMUC) announced today that it has achieved a key milestone in its research-stage Stem-to-T-Cell immuno-oncology program. The research team at ImmunoCellular successfully packaged a T cell receptor (TCR) DNA sequence into a lentiviral vector, which was then used to transfect human hematopoietic stem cells. The Company has been able to verify successful transfer of genetic material into the stem cells, and plans to continue to work toward optimizing the transfection process.
- Thomson Reuters StreetEvents•5 months ago
Edited Transcript of IMUC earnings conference call or presentation 21-Nov-17 10:00pm GMT
Q3 2017 ImmunoCellular Therapeutics Ltd Earnings Call
- PR Newswire•5 months ago
ImmuncoCellular Therapeutics to Present at the 10th Annual LD Micro Main Event on December 7, 2017
Live presentation will take place on December 7, 2017 at 9:30 a.m. PT (12:30 p.m. ET) LOS ANGELES , Nov. 22, 2017 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE American: ...
- PR Newswire•5 months ago
ImmunoCellular Therapeutics Announces Third Quarter 2017 Financial Results
-Continued Focus on Stem-to-T-Cell Program- -Strengthened Financial Condition- -Conference Call Today at 5:00 pm ET- LOS ANGELES , Nov. 21, 2017 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") ...
- ACCESSWIRE•5 months ago
ImmunoCellular Therapeutics, Ltd. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 21, 2017 / ImmunoCellular Therapeutics, Ltd. (NYSE MKT: IMUC ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 1, 2017 at ...
- PR Newswire•5 months ago
ImmunoCellular Therapeutics to Report Third Quarter 2017 Financial Results on November 21, 2017
LOS ANGELES , Nov. 17, 2017 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that it plans to report third quarter 2017 financial results ...
- PR Newswire•7 months ago
ImmunoCellular Therapeutics to Present at the Lytham Partners Virtual Investor Conference on October 11, 2017 at 2:00pm ET
Live presentation will take place on October 11, 2017 at 2:00pm ET / 11:00am PT; Replay available on demand LOS ANGELES , Oct. 3, 2017 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") ...
- ACCESSWIRE•7 months ago
ImmunoCellular, Innovative Cellular Platform, and Pipeline Review
NEW YORK, NY / ACCESSWIRE / September 19, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...
- PR Newswire•7 months ago
ImmunoCellular Therapeutics Announces NYSE MKT Acceptance of its Plan of Compliance
LOS ANGELES , Sept. 13, 2017 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (NYSE MKT: IMUC) today announced that the NYSE MKT LLC (the "NYSE ...
- Thomson Reuters StreetEvents•8 months ago
Edited Transcript of IMUC earnings conference call or presentation 23-Aug-17 9:00pm GMT
Q2 2017 ImmunoCellular Therapeutics Ltd Earnings Call